Expression of liver insulin-like growth factor 1 gene and its serum level in patients with XXXX .

@entity6 @entity10835 @entity2135 @entity35 @entity413
AIM: To explore the effect of @entity6 duration and blood @entity413 level on @entity2135 ( @entity2135 ) gene expression and serum @entity2135 level. METHODS: @entity6 was induced into @entity35 by @entity10835 and then the @entity35 were subdivided into different groups with varying blood @entity413 level and @entity6 duration. The parameters were measured as follows: @entity2135 mRNA by reverse transcriptase-polymerase chain reaction (RT-PCR), @entity2135 peptide and serum @entity2135 concentration by enzyme-linked immunosorbent assay (ELISA). RESULTS: During early @entity6 stage (week 2), in comparison with normal control group (NC), @entity2135 mRNA (1.17 +/- 0.069 vs 0.79 +/- 0.048, P<0.001; 1.17 +/- 0.069 vs 0.53 +/- 0.023, P<0.0005, respectively), @entity2135 peptide contents [(196.66 +/- 14.9) ng/mg(-1) vs (128.2 +/- 11.25) ng/mg(-1), P<0.0005; (196.66 +/- 14.9) ng/mg(-1) vs (74.43 +/- 5.33) ng/mg(-1), P<0.0001, respectively] were reduced in liver tissues of @entity6 @entity35 . The @entity2135 gene downregulation varied with @entity413 control level of the @entity6 state, and deteriorated gradually further with duration of @entity6 . By month 6, hepatic tissue @entity2135 mRNA was 0.71 +/- 0.024 vs 1.12 +/- 0.056, P<0.001; 0.47 +/- 0.021 vs 1.12 +/- 0.056, P<0.0005, respectively. @entity2135 peptide was (114.35 +/- 8.09) ng/mg(-1) vs (202.05 +/- 15.73) ng/mg(-1), P<0.0005; (64.58 +/- 3.89) ng/mg(-1) vs (202.05 +/- 15.73) ng/mg(-1), P<0.0001 respectively. Serum @entity2135 was also lowered in @entity6 group with poor control of blood @entity413 . On week 2, serum @entity2135 concentrations were (371.0 +/- 12.5) ng/mg(-1) vs (511.2 +/- 24.7) ng/mg(-1), P<0.0005, (223.2 +/- 9.39) ng/mg(-1) vs (511.2 +/- 24.7) ng/mg(-1), P<0.0001 respectively. By month 6, (349.6 +/- 18.62) ng/mg(-1) vs (520.7 +/- 26.32) ng/mg(-1), P<0.0005, (188.5 +/- 17.35 vs 520.7 +/- 26.32) ng/mg(-1), P<0.0001, respectively. Serum @entity2135 peptide change was significantly correlated with that in liver tissue (r=0.99, P<0.001). Furthermore, no difference was found in the above parameters between @entity6 @entity35 with euglycemia and non- @entity6 control group. CONCLUSION: The influence of @entity6 status on @entity2135 gene expression in liver tissues is started from early @entity6 stage, causing down regulation of @entity2135 expression, and progresses with the severity and duration of @entity6 state. Accordingly serum @entity2135 level decreases. This might indicate that liver tissue @entity2135 gene expression is greatly affected in @entity6 , thus contributing to reduction of serum @entity2135 level.
